

@article {2673,
	title = {Rotavirus vaccine-derived shedding and viral reassortants},
	journal = {Expert Review of Vaccines},
	volume = {11},
	number = {11},
	year = {2012},
	pages = {13111314},
	abstract = {{EVALUATION} {OF:} Donato {CM,} Ch{\textquoteright}ng {LS,} Boniface {KF} et al. Identification of strains of {RotaTeq} rotavirus vaccine in infants with gastroenteritis following routine vaccination. J. Infect. Dis. 206(3), 377{\textendash}383 {(2012).Two} live, attenuated rotavirus vaccines, {RotaTeq({\textregistered})} {(Merck)} and Rotarix({\textregistered}) {(GlaxoSmithKline),} have been used in Australia since July 2007 to prevent severe rotavirus gastroenteritis in children. Using active postvaccination monitoring, passive surveillance and state-of-the-art laboratory techniques, Donato et al. report that {RotaTeq} rotavirus vaccine and vaccine-derived strains were detected actively in stool samples from 13 out of 61 (21.3\%) infants having diarrhea within 2 weeks of rotavirus vaccination, and among three out of 460 (0.7\%) cases with acute gastroenteritis captured via the Australian Rotavirus Surveillance Program. Six (37.5\%) of these 16 vaccine-derived viral specimens were associated with a {G1P[8]} strain thought to be the result of genetic reassortment between two component {RotaTeq} strains. Although nearly half of these reassortant-associated cases had underlying medical conditions, such as severe combined immunodeficiency disorder, further study is needed to understand the relationship between shedding, viral reassortants and underlying medical conditions.},
	doi = {10.1586/erv.12.114},
	url = {http://dx.doi.org/10.1586/erv.12.114},
	author = {Michael D Bowen and Daniel C Payne}
}
